Monoclonal Gammopathy of Undetermined Significance: An Update for Nephrologists

9Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Screening for a monoclonal protein is a common part of the assessment of patients presenting with a renal injury. While in the settings of acute kidney injury, chronic kidney disease and proteinuria monoclonal proteins can be associated with significant pathologies such as cast nephropathy, amyloidosis, and light chain deposition disease, they can also be an unrelated finding. The purpose of this review is to provide the nephrologist with an update to the diagnostic assessment and risk stratification of monoclonal proteins to avoid unnecessary investigation and monitoring of those patients with low-risk monoclonal gammopathies. © 2012.

Cite

CITATION STYLE

APA

Parry, H. M., Pratt, G., & Hutchison, C. A. (2012, September). Monoclonal Gammopathy of Undetermined Significance: An Update for Nephrologists. Advances in Chronic Kidney Disease. https://doi.org/10.1053/j.ackd.2012.07.006

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free